Cargando…

Heterogeneity in the evaluation of suspected MIS-C: a cross-sectional vignette-based survey

BACKGROUND AND OBJECTIVES: Multisystem Inflammatory Syndrome in Children (MIS-C) is an emerging complication of COVID-19 which lacks a definitive diagnostic test and evidence-based guidelines for workup. We sought to assess practitioners' preferences when initiating a workup for pediatric patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosu, Claudia A., Martens, Anna M., Sumner, Jeffrey, Farkas, Eva J., Arya, Puneeta, Arauz, Alexy Boudreau, Madhavan, Vandana L., Chavez, Hector, Larson, Shawn D., Badaki-Makun, Oluwakemi, Irimia, Daniel, Yonker, Lael M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254446/
https://www.ncbi.nlm.nih.gov/pubmed/35787254
http://dx.doi.org/10.1186/s12887-022-03446-4
_version_ 1784740701383163904
author Rosu, Claudia A.
Martens, Anna M.
Sumner, Jeffrey
Farkas, Eva J.
Arya, Puneeta
Arauz, Alexy Boudreau
Madhavan, Vandana L.
Chavez, Hector
Larson, Shawn D.
Badaki-Makun, Oluwakemi
Irimia, Daniel
Yonker, Lael M.
author_facet Rosu, Claudia A.
Martens, Anna M.
Sumner, Jeffrey
Farkas, Eva J.
Arya, Puneeta
Arauz, Alexy Boudreau
Madhavan, Vandana L.
Chavez, Hector
Larson, Shawn D.
Badaki-Makun, Oluwakemi
Irimia, Daniel
Yonker, Lael M.
author_sort Rosu, Claudia A.
collection PubMed
description BACKGROUND AND OBJECTIVES: Multisystem Inflammatory Syndrome in Children (MIS-C) is an emerging complication of COVID-19 which lacks a definitive diagnostic test and evidence-based guidelines for workup. We sought to assess practitioners' preferences when initiating a workup for pediatric patients presenting with symptoms concerning for MIS-C. METHODS: In a cross-sectional vignette-based survey, providers were presented with clinical vignettes of a patient presenting with 24 h of fever from a community with high rates of COVID-19. Respondents were asked about their general practices in pursuing a workup for potential MIS-C including testing obtained, criteria for diagnosis, and timing to confirm or rule out the diagnosis. RESULTS: Most of the 174 respondents were physicians from the United States at academic medical centers. The majority of providers would not initiate MIS-C workup for fever and non-specific symptoms unless the fever lasted more than 72 h. Skin rash, abdominal pain, and shortness of breath were symptoms that raised greatest concern for MIS-C. Most providers would obtain COVID-19 PCR or antigen testing, plus blood work, in the initial workup. The list of laboratory studies providers would obtain is extensive. Providers primarily rely on cardiac involvement to confirm a MIS-C diagnosis, and establishing a diagnosis takes 24–48 h. CONCLUSIONS: Significant heterogeneity exists amongst providers as to when to initiate the MIS-C workup, the order and content of the workup, and how to definitively diagnose MIS-C. A diagnostic test with high sensitivity and specificity for MIS-C and refined evidence-based guidelines are needed to expedite diagnosis and treatment.
format Online
Article
Text
id pubmed-9254446
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92544462022-07-06 Heterogeneity in the evaluation of suspected MIS-C: a cross-sectional vignette-based survey Rosu, Claudia A. Martens, Anna M. Sumner, Jeffrey Farkas, Eva J. Arya, Puneeta Arauz, Alexy Boudreau Madhavan, Vandana L. Chavez, Hector Larson, Shawn D. Badaki-Makun, Oluwakemi Irimia, Daniel Yonker, Lael M. BMC Pediatr Research BACKGROUND AND OBJECTIVES: Multisystem Inflammatory Syndrome in Children (MIS-C) is an emerging complication of COVID-19 which lacks a definitive diagnostic test and evidence-based guidelines for workup. We sought to assess practitioners' preferences when initiating a workup for pediatric patients presenting with symptoms concerning for MIS-C. METHODS: In a cross-sectional vignette-based survey, providers were presented with clinical vignettes of a patient presenting with 24 h of fever from a community with high rates of COVID-19. Respondents were asked about their general practices in pursuing a workup for potential MIS-C including testing obtained, criteria for diagnosis, and timing to confirm or rule out the diagnosis. RESULTS: Most of the 174 respondents were physicians from the United States at academic medical centers. The majority of providers would not initiate MIS-C workup for fever and non-specific symptoms unless the fever lasted more than 72 h. Skin rash, abdominal pain, and shortness of breath were symptoms that raised greatest concern for MIS-C. Most providers would obtain COVID-19 PCR or antigen testing, plus blood work, in the initial workup. The list of laboratory studies providers would obtain is extensive. Providers primarily rely on cardiac involvement to confirm a MIS-C diagnosis, and establishing a diagnosis takes 24–48 h. CONCLUSIONS: Significant heterogeneity exists amongst providers as to when to initiate the MIS-C workup, the order and content of the workup, and how to definitively diagnose MIS-C. A diagnostic test with high sensitivity and specificity for MIS-C and refined evidence-based guidelines are needed to expedite diagnosis and treatment. BioMed Central 2022-07-04 /pmc/articles/PMC9254446/ /pubmed/35787254 http://dx.doi.org/10.1186/s12887-022-03446-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rosu, Claudia A.
Martens, Anna M.
Sumner, Jeffrey
Farkas, Eva J.
Arya, Puneeta
Arauz, Alexy Boudreau
Madhavan, Vandana L.
Chavez, Hector
Larson, Shawn D.
Badaki-Makun, Oluwakemi
Irimia, Daniel
Yonker, Lael M.
Heterogeneity in the evaluation of suspected MIS-C: a cross-sectional vignette-based survey
title Heterogeneity in the evaluation of suspected MIS-C: a cross-sectional vignette-based survey
title_full Heterogeneity in the evaluation of suspected MIS-C: a cross-sectional vignette-based survey
title_fullStr Heterogeneity in the evaluation of suspected MIS-C: a cross-sectional vignette-based survey
title_full_unstemmed Heterogeneity in the evaluation of suspected MIS-C: a cross-sectional vignette-based survey
title_short Heterogeneity in the evaluation of suspected MIS-C: a cross-sectional vignette-based survey
title_sort heterogeneity in the evaluation of suspected mis-c: a cross-sectional vignette-based survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254446/
https://www.ncbi.nlm.nih.gov/pubmed/35787254
http://dx.doi.org/10.1186/s12887-022-03446-4
work_keys_str_mv AT rosuclaudiaa heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT martensannam heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT sumnerjeffrey heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT farkasevaj heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT aryapuneeta heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT arauzalexyboudreau heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT madhavanvandanal heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT chavezhector heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT larsonshawnd heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT badakimakunoluwakemi heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT irimiadaniel heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey
AT yonkerlaelm heterogeneityintheevaluationofsuspectedmiscacrosssectionalvignettebasedsurvey